Drug delivery technologies and sustained release

OctoPlus has developed a number of proprietary drug delivery technologies that facilitate the controlled release of biologically active compounds. Our three main technology platforms enable us to develop tailor-made controlled release formulations for all classes of injectable drug compounds:

OctoDEX^®: a dextran-based microsphere delivery technology for proteins and particulate systems.

PolyActive^®: a biodegradable polymeric drug delivery system for the controlled release of proteins and lipophilic small molecules.

SynBiosys™: a biodegradable polymeric drug delivery system for the controlled release of peptides and small molecules (in collaboration with Innocore BV).

Vaccine delivery
Our platform technologies also offer unique advantages for the development of single-shot vaccines, and we are currently exploring these in a co-development programme for a single-shot Japanese encephalitis vaccine together with Singapore-based vaccine company SingVax .

Partnering opportunities
OctoPlus offers its drug delivery technologies for licensing to third parties on a product-by-product basis. The company has entered into a number of successful product partnerships with third parties to co-develop controlled release formulations.

For more information about our drug delivery technologies, please refer to our technical factsheets.